Psyence BioMed Expands Clinical Site Network in Australia to Five Locations for NPX-5 Trials

Psyence BioMed has announced the expansion of its clinical site network in Australia to a total of five locations. This development aims to support ongoing clinical activities involving NPX-5, a compound under investigation by the company. The additional sites are expected to enhance Psyence BioMed’s capacity for conducting research and trials related to its therapeutic initiatives.

The company stated that the expanded network will facilitate broader access for participants and streamline data collection processes across multiple regions. These efforts align with Psyence BioMed’s focus on advancing clinical studies for NPX-5, which is being evaluated for its potential applications in mental health treatment. The announcement marks a step forward in the company’s strategy to strengthen its research infrastructure and accelerate progress in its clinical programs.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI